CURE’s prostate cancer page is an extensive resource of cancer information featuring the latest prostate cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on prostate cancer.
April 19th 2024
From the Allman Brothers Band’s singer Dickey Betts dying after a cancer diagnosis to the “Shopaholic” author announcing her glioblastoma diagnosis, here’s what is happening in the cancer space this week.
After No-PSA-Screening Recommendation, Prostate Cancer is Diagnosed Less Frequently
August 8th 2015New diagnoses of prostate cancer have declined nearly 30 percent, a study has found, since the U.S. Preventive Services Task Force discouraged the routine use of prostate-specific antigen testing in 2011.
Test Case: Despite Debate, PSA Testing for Prostate Cancer Can Be a Life-Saving Measure
June 17th 2015When the USPSTF issued its recommendation against PSA testing, urologists nationwide, myself included, warned about the possible public health repercussions that could ensue. Our fears have materialized, and much sooner than anticipated.
FDA Approves Zytiga Label Update for Use in Chemo-Naive Men with Metastatic Prostate Cancer
March 31st 2015The FDA has updated the label for Zytiga plus prednisone to include data that detailed a significant prolongation in overall survival for Zytiga versus placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
Updated Analysis of Prostate Cancer Trials Continue to Demonstrate Benefit with Xtandi
March 24th 2015Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.
Men with Testicular Cancer More Likely to Develop Prostate Cancer
February 24th 2015A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared with those without a history of testicular cancer.